{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T00:00:00Z","timestamp":1790294400375,"version":"4.1.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T00:00:00Z","timestamp":1783123200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T00:00:00Z","timestamp":1790294400000},"content-version":"vor","delay-in-days":83,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cardiovasc Disord"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Direct oral anticoagulants (DOACs) are recommended over vitamin K antagonists (VKAs) for stroke prevention in patients with non-valvular atrial fibrillation (NVAF). However, real-world prescribing patterns and dosing appropriateness in low- and middle-income countries remain poorly characterized. This study evaluated patterns of oral anticoagulant use and identified clinical determinants of suboptimal prescribing in a tertiary cardiovascular center in Vietnam.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective observational study of 209 patients with NVAF who received oral anticoagulation at a tertiary cardiovascular center between 2023 and 2024. Data were extracted from electronic medical records, including demographics, comorbidities, renal function, bleeding history, and prescribed anticoagulants. Multivariable logistic regression was used to identify factors associated with anticoagulant selection, defined as DOAC versus VKA use. DOAC dosing appropriateness was assessed according to the 2021 European Heart Rhythm Association Practical Guide, and predictors of potentially inappropriate dose reduction were evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      DOACs were prescribed in 77.0% of patients, most commonly rivaroxaban, which accounted for 55.3% of all anticoagulant prescriptions. VKAs were prescribed in 23.0% of patients. Among VKA users, 85.4% had INR values outside the therapeutic range at admission, largely due to subtherapeutic international normalized ratio values. Reduced DOAC doses were prescribed in 88 of 161 DOAC users (54.7%). Among 85 assessable reduced-dose DOAC users, 42 (49.4%) were classified as having potentially inappropriate dose reduction. In the parsimonious multivariable model, age\u2009\u2265\u200975 years was associated with higher odds of DOAC use (odds ratio [OR] 5.08; 95% confidence interval [CI] 1.95\u201313.23;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.001), whereas female sex (OR 0.43; 95% CI 0.21\u20130.91;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.027), heart failure (OR 0.23; 95% CI 0.09\u20130.59;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.002), and prior bleeding (OR 0.20; 95% CI 0.05\u20130.87;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.031) were associated with lower odds of DOAC use.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In this single-center retrospective study from Vietnam, oral anticoagulant prescribing in patients with NVAF showed several areas for optimization, including frequent INR values outside the therapeutic range at admission among VKA users and frequent potentially inappropriate DOAC dose reduction. These findings support the need for improved dose optimization, and monitoring strategies, but should be interpreted cautiously give the observational design and inpatients data source.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12872-026-06188-8","type":"journal-article","created":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T07:18:32Z","timestamp":1783149512000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Oral anticoagulant prescribing and DOAC dosing appropriateness in patients with non-valvular atrial fibrillation: a retrospective study from Vietnam"],"prefix":"10.1186","volume":"26","author":[{"given":"Viet Anh","family":"Hoang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tuan Minh","family":"Le","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minh Vuong","family":"Nong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Van Thuong","family":"Bui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thi Ngoc Anh","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hoai Thi Thu","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan Co","family":"Dao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Van Giap","family":"Vu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"DaoVu","family":"Do","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,4]]},"reference":[{"issue":"8","key":"6188_CR1","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1161\/CIRCULATIONAHA.113.005119","volume":"129","author":"SS Chugh","year":"2014","unstructured":"Chugh SS, Havmoeller R, Narayanan K, Singh D, Rienstra M, Benjamin EJ, et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation. 2014;129(8):837\u201347. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.113.005119 . PubMed PMID: 24345399; PubMed Central PMCID: PMC4151302.","journal-title":"Circulation"},{"issue":"10","key":"6188_CR2","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1093\/europace\/euz","volume":"21","author":"A Di Carlo","year":"2019","unstructured":"Di Carlo A, Bellino L, Consoli D, Mori F, Zaninelli A, Baldereschi M, et al. Prevalence of atrial fibrillation in the Italian elderly population and projections from 2020 to 2060 for Italy and the European Union: the FAI Project. Europace. 2019;21(10):1468\u201375. https:\/\/doi.org\/10.1093\/europace\/euz. 141 PubMed PMID: 31131389.","journal-title":"Europace"},{"key":"6188_CR3","doi-asserted-by":"publisher","unstructured":"Ovid [Internet]. [cited 2026 Feb 26]. Factors that Contribute to the Failure of\u2026 International Journal of Heart Rhythm. Available from: https:\/\/www.ovid.com\/jnls\/ijhr\/fulltext\/10.4103\/ijhr.ijhr_2_24~factors-that-contribute-to-the-failure-of-thromboprophylaxishttps:\/\/doi.org\/10.4103\/IJHR.IJHR_2_24","DOI":"10.4103\/IJHR.IJHR_2_24"},{"issue":"1","key":"6188_CR4","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1161\/CIRCRESAHA.120.316340","volume":"127","author":"J Kornej","year":"2020","unstructured":"Kornej J, B\u00f6rschel CS, Benjamin EJ, Schnabel RB. Epidemiology of Atrial Fibrillation in the 21st Century: Novel Methods and New Insights. Circ Res. 2020;127(1):4\u201320. https:\/\/doi.org\/10.1161\/CIRCRESAHA.120.316340 . PubMed PMID: 32716709; PubMed Central PMCID: PMC7577553.","journal-title":"Circ Res"},{"issue":"2","key":"6188_CR5","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1177\/1747493019897870","volume":"16","author":"G Lippi","year":"2021","unstructured":"Lippi G, Sanchis-Gomar F, Cervellin G. Global epidemiology of atrial fibrillation: An increasing epidemic and public health challenge. Int J Stroke. 2021;16(2):217\u201321. https:\/\/doi.org\/10.1177\/1747493019897870.\u00a0PubMed PMID: 31955707.","journal-title":"Int J Stroke"},{"issue":"4","key":"6188_CR6","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1038\/s41569-020-00459-3","volume":"18","author":"A Kotalczyk","year":"2021","unstructured":"Kotalczyk A, Mazurek M, Kalarus Z, Potpara TS, Lip GYH. Stroke prevention strategies in high-risk patients with atrial fibrillation. Nat Rev Cardiol. 2021;18(4):276\u201390. https:\/\/doi.org\/10.1038\/s41569-020-00459-3.","journal-title":"Nat Rev Cardiol"},{"issue":"1","key":"6188_CR7","doi-asserted-by":"publisher","first-page":"9619","DOI":"10.1038\/s41598-025-91774-7","volume":"15","author":"F Li","year":"2025","unstructured":"Li F, Liu J, Zhang F, Wu X, Dai T, Kuang J, et al. Anticoagulation therapy after reperfusion treatment for acute ischemic stroke with non-valvular atrial fibrillation: a multicenter retrospective study. Sci Rep. 2025;15(1):9619. https:\/\/doi.org\/10.1038\/s41598-025-91774-7.","journal-title":"Sci Rep"},{"issue":"3","key":"6188_CR8","doi-asserted-by":"publisher","first-page":"CD001927","DOI":"10.1002\/14651858.CD001927.pub2","volume":"2005","author":"MI Aguilar","year":"2005","unstructured":"Aguilar MI, Hart R. Oral anticoagulants for preventing stroke in patients with non-valvular atrial fibrillation and no previous history of stroke or transient ischemic attacks. Cochrane Database Syst Rev. 2005;2005(3):CD001927. https:\/\/doi.org\/10.1002\/14651858.CD001927.pub2 . PubMed PMID: 16034869; PubMed Central PMCID: PMC8408914.","journal-title":"Cochrane Database Syst Rev"},{"key":"6188_CR9","unstructured":"Expert Review of the ESC 2024 Atrial Fibrillation Guidelines. 2025. Available from: https:\/\/aortahealth.com\/esc-2024-atrial-fibrillation-guidelines-stroke-prevention-and-rhythm-control\/.\u00a0cited 2026 Feb 26."},{"key":"6188_CR10","doi-asserted-by":"publisher","first-page":"107602962614168","DOI":"10.1177\/10760296261416892","volume":"32","author":"S Park","year":"2026","unstructured":"Park S, Je NK. Effectiveness and Safety of Direct Oral Anticoagulants versus Aspirin in Patients with Non-Valvular Atrial Fibrillation and Intermediate Stroke Risk. Clin Appl Thromb Hemost. 2026;32:10760296261416892. https:\/\/doi.org\/10.1177\/10760296261416892.\u00a0PubMed PMID: 41557516; PubMed Central PMCID: PMC12819969.","journal-title":"Clin Appl Thromb Hemost"},{"issue":"5","key":"6188_CR11","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","volume":"42","author":"G Hindricks","year":"2021","unstructured":"Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomstr\u00f6m-Lundqvist C, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021;42(5):373\u2013498. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa612 . PubMed PMID: 32860505.","journal-title":"Eur Heart J"},{"issue":"8","key":"6188_CR12","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1056\/NEJM199608223350802","volume":"335","author":"EM Hylek","year":"1996","unstructured":"Hylek EM, Skates SJ, Sheehan MA, Singer DE. An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. N Engl J Med. 1996;335(8):540\u20136. https:\/\/doi.org\/10.1056\/NEJM199608223350802.\u00a0PubMed PMID: 8678931.","journal-title":"N Engl J Med"},{"key":"6188_CR13","unstructured":"Dabigatran versus Warfarin in Patients with Atrial Fibrillation | New. England Journal of Medicine. [cited 2026 Feb 26]. Available from: https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa0905561."},{"issue":"4","key":"6188_CR14","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1161\/CIRCULATIONAHA.121.056355","volume":"145","author":"AP Carnicelli","year":"2022","unstructured":"Carnicelli AP, Hong H, Connolly SJ, Eikelboom J, Giugliano RP, Morrow DA, et al. Direct Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation: Patient-Level Network Meta-Analyses of Randomized Clinical Trials With Interaction Testing by Age and Sex. Circulation. 2022;145(4):242\u201355. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.121.056355 . PubMed PMID: 34985309; PubMed Central PMCID: PMC8800560.","journal-title":"Circulation"},{"key":"6188_CR15","unstructured":"2023 ACC\/AHA\/ACCP\/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. | Circulation. . Available from: https:\/\/www.ahajournals.org\/doi\/10.1161\/CIR.0000000000001193.\u00a0cited 2026 Feb 26."},{"issue":"1","key":"6188_CR16","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1186\/s12877-025-05960-3","volume":"25","author":"YT Zhang","year":"2025","unstructured":"Zhang YT, Liu JP, Zhao ZN, Gu HQ, Na YF, Zhang TQ, et al. Inappropriate dosing of direct oral anticoagulants among very older inpatients with atrial fibrillation. BMC Geriatr. 2025;25(1):292. https:\/\/doi.org\/10.1186\/s12877-025-05960-3.","journal-title":"BMC Geriatr"},{"key":"6188_CR17","doi-asserted-by":"publisher","unstructured":"Shen NN, Zhang C, Hang Y, Li Z, Kong LC, Wang N, et al. Real-World Prevalence of Direct Oral Anticoagulant Off-Label Doses in Atrial Fibrillation: An Epidemiological Meta-Analysis. Front Pharmacol. 2021;12. https:\/\/doi.org\/10.3389\/fphar.2021.581293.","DOI":"10.3389\/fphar.2021.581293"},{"key":"6188_CR18","unstructured":"Effect of non-recommended. doses versus recommended doses of direct oral anticoagulants in atrial fibrillation patients: A meta\u2010analysis - Liu\u2009\u2013\u20092021 - Clinical Cardiology - Wiley Online Library. Available from: https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/clc.23586.\u00a0cited 2026 Feb 26."},{"issue":"3","key":"6188_CR19","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1007\/s00277-015-2566-x","volume":"95","author":"JK Schaefer","year":"2016","unstructured":"Schaefer JK, McBane RD, Wysokinski WE. How to choose appropriate direct oral anticoagulant for patient with nonvalvular atrial fibrillation. Ann Hematol. 2016;95(3):437\u201349. https:\/\/doi.org\/10.1007\/s00277-015-2566-x . PubMed PMID: 26658769; PubMed Central PMCID: PMC4742513.","journal-title":"Ann Hematol"},{"issue":"2","key":"6188_CR20","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1177\/0272989X221121350","volume":"43","author":"KA Martinez","year":"2023","unstructured":"Martinez KA, Linfield DT, Shaker V, Rothberg MB. Informed Decision Making for Anticoagulation Therapy for Atrial Fibrillation. Med Decis Mak. 2023;43(2):263\u20139. https:\/\/doi.org\/10.1177\/0272989X221121350.\u00a0PubMed PMID: 36059267; PubMed Central PMCID: PMC9825626.","journal-title":"Med Decis Mak"},{"issue":"2","key":"6188_CR21","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1378\/chest.09-1584","volume":"137","author":"GYH Lip","year":"2010","unstructured":"Lip GYH, Nieuwlaat R, Pisters R, Lane DA, Crijns HJGM. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010;137(2):263\u201372. https:\/\/doi.org\/10.1378\/chest.09-1584 . PubMed PMID: 19762550.","journal-title":"Chest"},{"key":"6188_CR22","doi-asserted-by":"publisher","first-page":"d124","DOI":"10.1136\/bmj.d124","volume":"342","author":"JB Olesen","year":"2011","unstructured":"Olesen JB, Lip GYH, Hansen ML, Hansen PR, Tolstrup JS, Lindhardsen J, et al. Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. BMJ. 2011;342:d124. https:\/\/doi.org\/10.1136\/bmj.d124 . PubMed PMID: 21282258; PubMed Central PMCID: PMC3031123.","journal-title":"BMJ"},{"issue":"9","key":"6188_CR23","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1002\/clc.22435","volume":"38","author":"W Zhu","year":"2015","unstructured":"Zhu W, He W, Guo L, Wang X, Hong K. The HAS-BLED Score for Predicting Major Bleeding Risk in Anticoagulated Patients With Atrial Fibrillation: A Systematic Review and Meta-analysis. Clin Cardiol. 2015;38(9):555\u201361. https:\/\/doi.org\/10.1002\/clc.22435 . PubMed PMID: 26418409; PubMed Central PMCID: PMC6490831.","journal-title":"Clin Cardiol"},{"issue":"5","key":"6188_CR24","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1378\/chest.10-0134","volume":"138","author":"R Pisters","year":"2010","unstructured":"Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJGM, Lip GYH. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010;138(5):1093\u2013100. https:\/\/doi.org\/10.1378\/chest.10-0134 . PubMed PMID: 20299623.","journal-title":"Chest"},{"issue":"6","key":"6188_CR25","doi-asserted-by":"publisher","first-page":"e01012","DOI":"10.1002\/prp2","volume":"10","author":"A Lenglet","year":"2022","unstructured":"Lenglet A, Qazi JZ, Boivin Proulx LA, Legault C, Dorais M, Perreault S. Trends of use and factors that determine the choice of oral anticoagulants in women and men with atrial fibrillation. Pharmacol Res Perspect. 2022;10(6):e01012. https:\/\/doi.org\/10.1002\/prp2. 1012 PubMed PMID: 36413058; PubMed Central PMCID: PMC9680728.","journal-title":"Pharmacol Res Perspect"},{"issue":"16","key":"6188_CR26","doi-asserted-by":"publisher","first-page":"3234","DOI":"10.1007\/s11606-024-08871-y","volume":"39","author":"CH Weng","year":"2024","unstructured":"Weng CH, Kuo HK, Aho B, McGookin ED, Chan PA. Factors Correlated with Anticoagulation Choice in Primary Care Patients with Atrial Fibrillation and High Stroke Risk. J Gen Intern Med. 2024;39(16):3234\u201342. https:\/\/doi.org\/10.1007\/s11606-024-08871-y . PubMed PMID: 38937360; PubMed Central PMCID: PMC11618273.","journal-title":"J Gen Intern Med"},{"issue":"10","key":"6188_CR27","doi-asserted-by":"publisher","first-page":"4264","DOI":"10.1007\/s12325-023-02544-8","volume":"40","author":"K Hahn","year":"2023","unstructured":"Hahn K, Lamparter M. Prescription of DOACs in Patients with Atrial Fibrillation at Different Stages of Renal Insufficiency. Adv Ther. 2023;40(10):4264\u201381. https:\/\/doi.org\/10.1007\/s12325-023-02544-8 . PubMed PMID: 37594666; PubMed Central PMCID: PMC10499752.","journal-title":"Adv Ther"},{"issue":"5","key":"6188_CR28","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1097\/MNH.0000000000000634","volume":"29","author":"TA Mavrakanas","year":"2020","unstructured":"Mavrakanas TA, Charytan DM, Winkelmayer WC. Direct oral anticoagulants in chronic kidney disease: an update. Curr Opin Nephrol Hypertens. 2020;29(5):489\u201396. https:\/\/doi.org\/10.1097\/MNH.0000000000000634.\u00a0PubMed PMID: 32740218; PubMed Central PMCID: PMC7769201.","journal-title":"Curr Opin Nephrol Hypertens"},{"issue":"2","key":"6188_CR29","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.ihj.2021.02.003","volume":"73","author":"V Ramakumar","year":"2021","unstructured":"Ramakumar V, Benz AP, Karthikeyan G. Long-term oral anticoagulation for atrial fibrillation in low and middle income countries. Indian Heart J. 2021;73(2):244\u20138. https:\/\/doi.org\/10.1016\/j.ihj.2021.02.003 . PubMed PMID: 33865530; PubMed Central PMCID: PMC8065364.","journal-title":"Indian Heart J"},{"issue":"2","key":"6188_CR30","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1002\/clc.22596","volume":"40","author":"K Okumura","year":"2017","unstructured":"Okumura K, Hori M, Tanahashi N, John Camm A. Special considerations for therapeutic choice of non-vitamin K antagonist oral anticoagulants for Japanese patients with nonvalvular atrial fibrillation. Clin Cardiol. 2017;40(2):126\u201331. https:\/\/doi.org\/10.1002\/clc.22596 . PubMed PMID: 27716968; PubMed Central PMCID: PMC5347841.","journal-title":"Clin Cardiol"},{"issue":"10","key":"6188_CR31","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1093\/europace\/euab065","volume":"23","author":"J Steffel","year":"2021","unstructured":"Steffel J, Collins R, Antz M, Cornu P, Desteghe L, Haeusler KG, et al. 2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation. Europace. 2021;23(10):1612\u201376. https:\/\/doi.org\/10.1093\/europace\/euab065 . PubMed PMID: 33895845; PubMed Central PMCID: PMC11636576.","journal-title":"Europace"},{"key":"6188_CR32","doi-asserted-by":"publisher","first-page":"100044","DOI":"10.1016\/j.rpth.2023.100044","volume":"7","author":"MH Tran","year":"2023","unstructured":"Tran MH, Nguyen H, Mai Q, Pham Hong T. Knowledge and medication adherence of oral anticoagulant-taking patients in Vietnam. Res Pract Thromb Haemostasis. 2023;7:100044. https:\/\/doi.org\/10.1016\/j.rpth.2023.100044.","journal-title":"Res Pract Thromb Haemostasis"},{"issue":"4","key":"6188_CR33","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.jclinepi.2007.11.008","volume":"61","author":"E von Elm","year":"2008","unstructured":"von Elm E, Altman DG, Egger M, Pocock SJ, G\u00f8tzsche PC, Vandenbroucke JP, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol. 2008;61(4):344\u20139. PubMed PMID: 18313558.","journal-title":"J Clin Epidemiol"},{"key":"6188_CR34","unstructured":"The Asia-Pacific. perspective: redefining obesity and its treatment. Available from: https:\/\/iris.who.int\/items\/a74d8440-5c1d-4237-9559-3f729058587b. cited 2026 Mar 1."},{"issue":"33","key":"6188_CR35","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","volume":"39","author":"B Williams","year":"2018","unstructured":"Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018 ESC\/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021\u2013104. https:\/\/doi.org\/10.1093\/eurheartj\/ehy339 . PubMed PMID: 30165516.","journal-title":"Eur Heart J"},{"key":"6188_CR36","doi-asserted-by":"publisher","unstructured":"American Diabetes Association Professional Practice Committee. 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes\u20142024. Diabetes Care. 2023;47(Supplement_1):S20\u201342. https:\/\/doi.org\/10.2337\/dc24-S002","DOI":"10.2337\/dc24-S002"},{"issue":"36","key":"6188_CR37","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","volume":"42","author":"TA McDonagh","year":"2021","unstructured":"McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, B\u00f6hm M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599\u2013726. https:\/\/doi.org\/10.1093\/eurheartj\/ehab368 . PubMed PMID: 34447992.","journal-title":"Eur Heart J"},{"issue":"19","key":"6188_CR38","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1056\/NEJMoa2102953","volume":"385","author":"LA Inker","year":"2021","unstructured":"Inker LA, Eneanya ND, Coresh J, Tighiouart H, Wang D, Sang Y, et al. New Creatinine- and Cystatin C-Based Equations to Estimate GFR without Race. N Engl J Med. 2021;385(19):1737\u201349. https:\/\/doi.org\/10.1056\/NEJMoa2102953 . PubMed PMID: 34554658; PubMed Central PMCID: PMC8822996.","journal-title":"N Engl J Med"},{"key":"6188_CR39","unstructured":"Standardized Bleeding Definitions for Cardiovascular Clinical Trials. | Circulation. . Available from: https:\/\/www.ahajournals.org\/doi\/10.1161\/circulationaha.110.009449.\u00a0cited 2026 Mar 1."},{"key":"6188_CR40","unstructured":"Haemoglobin concentrations for the diagnosis of. anaemia and assessment of severity. Available from: https:\/\/www.who.int\/publications\/i\/item\/WHO-NMH-NHD-MNM-11.1.\u00a0cited 2026 Mar 1."},{"issue":"2","key":"6188_CR41","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.amjmed.2010.05.007","volume":"124","author":"GYH Lip","year":"2011","unstructured":"Lip GYH. Implications of the CHA(2)DS(2)-VASc and HAS-BLED Scores for thromboprophylaxis in atrial fibrillation. Am J Med. 2011;124(2):111\u20134. https:\/\/doi.org\/10.1016\/j.amjmed.2010.05.007 . PubMed PMID: 20887966.","journal-title":"Am J Med"},{"key":"6188_CR42","doi-asserted-by":"crossref","unstructured":"Application of Logistic Regression with Different Sampling Models. In: Applied Logistic Regression. John Wiley & Sons, Ltd. 2000. p. 203\u201322. Available fromhttps:\/\/onlinelibrary.wiley.com\/doi\/abs\/10.1002\/0471722146.ch6.\u00a0cited 2026 Mar 22.","DOI":"10.1002\/0471722146.ch6"},{"issue":"3","key":"6188_CR43","doi-asserted-by":"publisher","first-page":"837","DOI":"10.2307\/2531595","volume":"44","author":"ER DeLong","year":"1988","unstructured":"DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988;44(3):837\u201345. PubMed PMID: 3203132.","journal-title":"Biometrics"},{"key":"6188_CR44","unstructured":"Odom G. An R Cookbook for Public Health\u2009\u2013\u200920 Multiple Linear Regression [Internet]. 2024 [cited 2026 Mar 22]. Available from: https:\/\/gabrielodom.github.io\/PHC6099_rBiostat\/lessons_original\/04_regression_mls.html?utm_source=chatgpt.com"},{"issue":"6","key":"6188_CR45","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.3390\/jcm9061969","volume":"9","author":"M Kozie\u0142","year":"2020","unstructured":"Kozie\u0142 M, Mazurek M, Teutsch C, Diener HC, Dubner SJ, Halperin JL, et al. Persistence with Anticoagulation for Atrial Fibrillation: Report from the GLORIA-AF Phase III 1-Year Follow-up. J Clin Med. 2020;9(6):1969. https:\/\/doi.org\/10.3390\/jcm9061969.","journal-title":"J Clin Med"},{"key":"6188_CR46","doi-asserted-by":"publisher","unstructured":"Brugada J, Katritsis DG, Arbelo E, Arribas F, Bax JJ, Blomstr\u00f6m-Lundqvist C et al. 2019 ESC Guidelines for the management of patients with supraventricular tachycardiaThe Task Force for the management of patients with supraventricular tachycardia of the European Society of Cardiology (ESC): Developed in collaboration with the Association for European Paediatric and Congenital Cardiology (AEPC) [Internet]. [cited 2026 Mar 2]. Available from: https:\/\/doi.org\/10.1093\/eurheartj\/ehz467","DOI":"10.1093\/eurheartj\/ehz467"},{"issue":"1","key":"6188_CR47","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.jacasi.2024.10.027","volume":"5","author":"R Krittayaphong","year":"2025","unstructured":"Krittayaphong R, Winijkul A, Rungpradubvong V, Apiyasawat S, Phrommintikul A, Chantrarat T, et al. The COOL-AF Phase 2 Registry. JACC Asia. 2025;5(1):191\u2013202. https:\/\/doi.org\/10.1016\/j.jacasi.2024.10.027 . PubMed PMID: 39896253; PubMed Central PMCID: PMC11782006.","journal-title":"JACC Asia"},{"key":"6188_CR48","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.thromres.2020","volume":"196","author":"SG Ma","year":"2020","unstructured":"Ma SG, Hu J, Huang Y. The risk factors for perioperative venous thromboembolism in patients with gynecological malignancies: A meta-analysis. Thromb Res. 2020;196:325\u201334. https:\/\/doi.org\/10.1016\/j.thromres.2020.09.019. PubMed PMID: 32977132.","journal-title":"Thromb Res"},{"issue":"9","key":"6188_CR49","doi-asserted-by":"publisher","first-page":"e031341","DOI":"10.1136\/bmjopen-2019-031341","volume":"9","author":"Rodr\u00edguezLA Garc\u00eda","year":"2019","unstructured":"Garc\u00eda Rodr\u00edguezLA, Mart\u00edn-P\u00e9rez M, Vora P, Roberts L, Balabanova Y, Brobert G, et al. Appropriateness of initial dose of non-vitamin K antagonist oral anticoagulants in patients with non-valvular atrial fibrillation in the UK. BMJ Open. 2019;9(9):e031341. https:\/\/doi.org\/10.1136\/bmjopen-2019-031341 . PubMed PMID: 31542760; PubMed Central PMCID: PMC6756330.","journal-title":"BMJ Open"},{"issue":"11","key":"6188_CR50","doi-asserted-by":"publisher","first-page":"5700","DOI":"10.3390\/ijerph18115700","volume":"18","author":"MR Dalmau Llorca","year":"2021","unstructured":"Dalmau Llorca MR, Aguilar Mart\u00edn C, Carrasco-Querol N, Hern\u00e1ndez Rojas Z, Forcadell Drago E, Rodr\u00edguez Cumplido D, et al. Anticoagulation Control with Acenocoumarol or Warfarin in Non-Valvular Atrial Fibrillation in Primary Care (Fantas-TIC Study). Int J Environ Res Public Health. 2021;18(11):5700. https:\/\/doi.org\/10.3390\/ijerph18115700.","journal-title":"Int J Environ Res Public Health"},{"key":"6188_CR51","doi-asserted-by":"publisher","first-page":"e61","DOI":"10.15420\/ecr.2023.24","volume":"18","author":"TH Quang Ho","year":"2023","unstructured":"Quang Ho TH, Ton MT, Nguyen VL, Pham HM, Hoang SV, Vo NT, et al. Selection of Non-vitamin K Antagonist Oral Anticoagulant for Stroke Prevention in Atrial Fibrillation Based on Patient Profile: Perspectives from Vietnamese Experts. Part 1. Eur Cardiol. 2023;18:e61. https:\/\/doi.org\/10.15420\/ecr.2023.24 . PubMed PMID: 38174217; PubMed Central PMCID: PMC10762681.","journal-title":"Eur Cardiol"},{"key":"6188_CR52","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1186\/s12872-025-04703-x","volume":"25","author":"F Qi","year":"2025","unstructured":"Qi F, Wu J, Xia Z, Xie S, Chen X, Zheng H, et al. Clinical characteristics, adherence to anticoagulation therapy and prognosis in patients with atrial fibrillation: a real-life study. BMC Cardiovasc Disord. 2025;25:263. https:\/\/doi.org\/10.1186\/s12872-025-04703-x . PubMed PMID: 40189518; PubMed Central PMCID: PMC11974184.","journal-title":"BMC Cardiovasc Disord"},{"issue":"703","key":"6188_CR53","doi-asserted-by":"publisher","first-page":"e134","DOI":"10.3399\/bjgp20X","volume":"71","author":"E Ferrat","year":"2021","unstructured":"Ferrat E, Fabre J, Galletout P, Boutin E, Le Breton J, Renard V, et al. Inappropriate direct oral anticoagulant prescriptions in patients with non-valvular atrial fibrillation: cross-sectional analysis of the French CACAO cohort study in primary care. Br J Gen Pract. 2021;71(703):e134\u20139. https:\/\/doi.org\/10.3399\/bjgp20X714005. PubMed PMID: 33495204; PubMed Central PMCID: PMC7846350.","journal-title":"Br J Gen Pract"},{"issue":"4","key":"6188_CR54","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1253\/circj.CJ","volume":"83","author":"N Murata","year":"2019","unstructured":"Murata N, Okumura Y, Yokoyama K, Matsumoto N, Tachibana E, Kuronuma K, et al. Clinical Outcomes of Off-Label Dosing of Direct Oral Anticoagulant Therapy Among Japanese Patients With Atrial Fibrillation Identified From the SAKURA AF Registry. Circ J. 2019;83(4):727\u201335. https:\/\/doi.org\/10.1253\/circj.CJ-18-0991. PubMed PMID: 30726797.","journal-title":"Circ J"},{"issue":"12","key":"6188_CR55","doi-asserted-by":"publisher","first-page":"e014177","DOI":"10.1161\/JAHA.119.014177","volume":"9","author":"HT Yu","year":"2020","unstructured":"Yu HT, Yang PS, Jang E, Kim TH, Uhm JS, Kim JY, et al. Label Adherence of Direct Oral Anticoagulants Dosing and Clinical Outcomes in Patients With Atrial Fibrillation. J Am Heart Assoc. 2020;9(12):e014177. https:\/\/doi.org\/10.1161\/JAHA.119.014177 . PubMed PMID: 32495677; PubMed Central PMCID: PMC7429045.","journal-title":"J Am Heart Assoc"},{"issue":"9","key":"6188_CR56","doi-asserted-by":"publisher","first-page":"2574","DOI":"10.1161\/STROKEAHA.119.025623","volume":"50","author":"WH Cheng","year":"2019","unstructured":"Cheng WH, Chao TF, Lin YJ, Chang SL, Lo LW, Hu YF, et al. Low-Dose Rivaroxaban and Risks of Adverse Events in Patients With Atrial Fibrillation. Stroke. 2019;50(9):2574\u20137. https:\/\/doi.org\/10.1161\/STROKEAHA.119.025623.\u00a0PubMed PMID: 31288672.","journal-title":"Stroke"},{"issue":"23","key":"6188_CR57","doi-asserted-by":"publisher","first-page":"2779","DOI":"10.1016\/j.jacc.2017.03.600","volume":"69","author":"X Yao","year":"2017","unstructured":"Yao X, Shah ND, Sangaralingham LR, Gersh BJ, Noseworthy PA, Non-Vitamin K. Antagonist Oral Anticoagulant Dosing in Patients With Atrial Fibrillation and Renal Dysfunction. J Am Coll Cardiol. 2017;69(23):2779\u201390. https:\/\/doi.org\/10.1016\/j.jacc.2017.03.600 . PubMed PMID: 28595692.","journal-title":"J Am Coll Cardiol"},{"issue":"24","key":"6188_CR58","doi-asserted-by":"publisher","first-page":"2597","DOI":"10.1016\/j.jacc.2016.09","volume":"68","author":"BA Steinberg","year":"2016","unstructured":"Steinberg BA, Shrader P, Thomas L, Ansell J, Fonarow GC, Gersh BJ, et al. Off-Label Dosing of Non-Vitamin K Antagonist Oral Anticoagulants and Adverse Outcomes: The ORBIT-AF II Registry. J Am Coll Cardiol. 2016;68(24):2597\u2013604. https:\/\/doi.org\/10.1016\/j.jacc.2016.09. .966 PubMed PMID: 27978942.","journal-title":"J Am Coll Cardiol"}],"container-title":["BMC Cardiovascular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12872-026-06188-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-026-06188-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-026-06188-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T23:19:59Z","timestamp":1790291999000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12872-026-06188-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,4]]},"references-count":58,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["6188"],"URL":"https:\/\/doi.org\/10.1186\/s12872-026-06188-8","relation":{},"ISSN":["1471-2261"],"issn-type":[{"value":"1471-2261","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,4]]},"assertion":[{"value":"13 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study involved human participant data and was conducted in accordance with the principles of the World Medical Association Declaration of Helsinki. The study was approved by the local Hospital Ethics Committee of Bach Mai Hospital, Vietnam National Heart Institute, Hanoi, Vietnam (Decision No. 7395\/QD-BM, December 15, 2025). Because of the retrospective design and the use of de-identified data, the requirement for individual informed consent was waived by the ethics committee.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. This manuscript does not contain any individual person\u2019s identifiable data, images, or videos.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"838"}}